Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Highlighting the advantages of neoantigen mRNA vaccines in melanoma

Adnan Khattak • 4 Jun 2023
ASCO 2023
Melanoma Skin Cancer Antibodies Checkpoint Inhibitors

Current treatment options for patients with melanoma include immune checkpoint inhibitors and targeted therapies such as BRAF inhibitors. Adnan Khattak, MBBS, FRACP, Royal Perth Hospital, Perth, Australia, describes the benefits of cancer vaccines over available therapies. The mRNA vaccines are personalized, and are specific to tumor mutations found in the individual patient, where up to 34 neoantigens can be targeted. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Adnan Khattak

0:52
Novel advances in PD-1 refractory melanoma
Adnan Khattak • 4 Jun 2023
1:39
Unanswered questions in the use of mRNA-based personalized cancer vaccines
Adnan Khattak • 4 Jun 2023
2:14
KEYNOTE-942: DMFS findings of a personalized mRNA vaccine in melanoma
Adnan Khattak • 4 Jun 2023

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals